pharma · Sickle Cell Disease
theravia
THERAVIA
THERAVIA is a pharma organization headquartered in EU. Primary therapeutic focus areas include Sickle Cell Disease. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity fro
FR HQ
2023 Founded
34 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- FR
- Founded
- 2023
- Employees
- 34
- Programs
- 1
- Drugs
- 4
- Patents
- 0
SIKLOS PAEDIATRIC 50mg dispersible tablets
Phase 2 · small molecule · Sickle Cell Disease
SIKLOS PAEDIATRIC 50mg dispersible tablets for Sickle Cell Disease is a Phase 2 program (small_molecule) at THERAVIA with 1 ClinicalTrials.gov record(s).
Internal code SIK-FR-24-1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- THERAVIA
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Sickle Cell Disease
- Status
- active
- Trials
- 1